Fig. 3

CAP1 induces ES in HAEC and CAEC. (A) Representative immunoblot detection of CAP1 in HAEC and CAEC from P1 to P12. (N = 3 Mean ± SD. *p < 0.05. ^#p < 0.01. ^$p < 0.001 P1 vs. selected passages). (B) Representative immunoblot detection of CAP1 in conditioned medium of HAEC and CAEC from P1 to P12. (N = 3 Mean ± SD. *p < 0.05. P1 vs. selected passages). (C) Senescence-associated Β-gal (SABG) staining of P1 HAEC and CAEC incubated 24 h with 2 ml culture medium from P1-12 HAEC and CAEC as indicated (N = 3 Mean ± SD. *p < 0.05. ^**p < 0.01. P1 vs. selected passages). (D) CAP1 silenced HAEC and CAEC representative immunoblot shows. N = 3 Mean ± SD. *p < 0.05 CAP1 siRNA vs. CONTROL. (E) CAP1 silenced HAEC and CAEC overexpressing CAP1 (after transfection of pCAP1 ), as shown by representative immunoblot. N = 3 Mean ± SD. *p < 0.05 CAP1 siRNA vs. CAP1 siRNA/pCAP1. (F) Representative immunoblot detection of PCSK9 in HAEC and CAEC from P1 to P12. (N = 3 Mean ± SD). (G) ES assay in HAEC and CAEC incubated with 100 mM PCSK9 inhibitor Evolocumab. N = 3 Mean ± SD. (H) ES assay in Evolocumab incubated cells as in B. N = 3 Mean ± SD, *p < 0.05, and ^#p < 0.05 CONTROL vs. CAP1 siRNA in HAEC and CAEC, respectively. ^@p < 0.05 HAEC CAP1 siRNA/pCAP1 and CAP1 siRNA/pCAP1/Evo vs. CONTROL. ^$p < 0.05 CAEC CAP1 siRNA/pCAP1 and CAP1 siRNA/pCAP1/Evo vs. CONTROL